Table 1.
Baseline demographic data of patients with JIA at MTX start and age-matched controls
| Characteristic | JIA patients (all) | JIA R | JIA NR | Controls |
|---|---|---|---|---|
| Number of cases | 47 | 29 | 18 | 14 |
| Gender, female, n (%) | 38 (81) | 25 (86) | 13 (72) | 10 (71) |
| JIA subtype, n (%) | ||||
| Oligoarticular persistent | 3 (6) | 2 (7) | 1 (6) | |
| Oligoarticular extended | 3 (6) | 3 (10) | 0 (0) | |
| Polyarticular RF− | 32 (68) | 17 (59) | 15 (83) | |
| Polyarticular RF+ | 9 (19) | 7 (24) | 2 (11) | |
| Clinical variables | ||||
| Disease duration at starting MTX, decimal years | 0.6 (0.3–1.6) | 0.6 (0.3–1.2) | 0.6 (0.3–1.6) | |
| Age at starting MTX, decimal years | 11.8 (7.2–15.4) | 13.0 (8.8–15.3) | 9.7 (5.7–14.7) | |
| Physician’s VAS | 5 (4–7) | 5 (4–7) | 5 (4–6.8) | |
| Active joints | 9 (5–17.5) | 9 (5–12) | 13 (4.5–19.5) | |
| Restricted joints | 6 (2–12) | 4.5 (2–9.3) | 7 (4.3–21.3) | |
| Parent’s VAS | 3 (1.5–6.7) | 3 (1.4–6.3) | 4 (1.5–7.9) | |
| CHAQ | 0.4 (0–1.13) | 0.4 (0.03–0.96) | 0.7 (0.03–1.41) | |
| ESR, mm/h | 25 (8–42) | 12.5 (5.75–30) | 33 (28–49) | |
| MTX dose, mg/m2 | 11.4 (9.1–13.3) | 10.6 (8.3–13.0) | 12.3 (10.2–13.7) | |
Data are the median and interquartile range, unless otherwise indicated. CHAQ: childhood health assessment questionnaire; NR: non-responder; R: responder; VAS: visual analogue scale.